Every Form 4 that Citius Oncology, Inc. (CTOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CTOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTOR filings page.
Myron Z. Holubiak, a director and the company secretary of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings. On 09/19/2025 he received 850,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continued service. The filing also reports 100,000 restricted shares granted the same day to his daughter, for which he disclaims beneficial ownership. Previously granted options include 300,000 options (exercise price $1.07) held directly and 50,000 options held indirectly by his daughter, both from a 12/12/2024 grant with 3-year vesting, plus 1,500,000 options (exercise price $2.15) from a 07/05/2023 grant that vest over three years.
Robert Joseph Smith, a director of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings on Form 4. The filing shows a grant of 300,000 restricted shares on 09/19/2025 that vest in three substantially equal annual installments subject to continued service. The report also discloses ownership of 125,000 stock options granted 12/12/2024 with an exercise price of $1.07, exercisable in thirds on each anniversary and expiring 12/12/2034. After the reported restricted-stock grant, the filing lists 300,000 shares beneficially owned directly by the reporting person.
Leonard L. Mazur, Chief Executive Officer and Director of Citius Oncology, Inc. (CTOR), received equity awards on 09/19/2025 that materially change his beneficial ownership. The Form 4 reports a grant of 1,700,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. The filing also shows outstanding stock options: 800,000 options with a $1.07 exercise price and 3,700,000 options with a $2.15 exercise price, each with multi-year vesting schedules. These awards reflect compensation through equity with time-based vesting conditions tied to continued service.
Citius Oncology director Carol Webb received equity compensation disclosed on Form 4. On 09/19/2025 she was granted 300,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continuous service. The filing also shows two stock option awards: 125,000 options with a $1.07 exercise price (granted 12/12/2024) and 150,000 options with a $2.15 exercise price (granted 07/05/2023). The 125,000 options vest over three years and the 150,000 options are fully vested. Ownership following the reported transactions is 300,000 shares directly beneficially owned.
Citius Oncology insider equity grants reported by Chief Medical Officer Myron Czuczman. The filing shows restricted stock awards of 825,000 shares granted on 09/19/2025 that vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds two stock option grants: 400,000 options with a $1.07 exercise price and a 12/12/2034 date shown, and 1,400,000 options with a $2.15 exercise price and a 07/05/2033 date; vesting schedules for the options are described in the filing. All holdings are reported as direct beneficial ownership.
Reporting person: Dennis M. McGrath, Director of Citius Oncology, Inc. (CTOR). Transaction: On 09/19/2025 Mr. McGrath was granted 300,000 restricted common shares at $0, which vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. He also holds two previously reported option grants: a $1.07 exercise-price option for 125,000 shares (granted 12/12/2024; vests one-third each year over three years) and a $2.15 exercise-price option for 150,000 shares (100% vested). Following the 09/19/2025 award, Mr. McGrath beneficially owns 300,000 shares directly plus the options described above. The Form 4 was signed by power of attorney on 09/23/2025.
Jaime Bartushak, Chief Financial Officer of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings on a Form 4. On 09/19/2025 she was granted 825,000 restricted stock awards at no cash price; those shares vest in three substantially equal installments on each of the first three anniversaries of the grant, subject to continued service. The filing also shows two outstanding stock option awards held directly: 400,000 options with a $1.07 exercise price (granted 12/12/2024) and 1,400,000 options with a $2.15 exercise price (vesting began 7/5/2023). The Form was signed by a power of attorney on 09/23/2025.
Citius Oncology director Joel David Mayersohn received 300,000 restricted shares on 09/19/2025, increasing his direct ownership to 321,228 shares. The restricted shares were granted at no cash price and vest in three substantially equal installments on each of the first, second and third anniversaries of the grant date, subject to continued service to the company or a related entity. The filing also reports existing stock options granted 12/12/2024 with an exercise price of $1.07 covering 250,000 underlying shares; those options vest one-third on each of the first, second and third anniversaries of the grant date and are recorded as 250,000 options held directly.
Suren G. Dutia, a director of Citius Oncology, acquired 300,000 restricted shares on 09/19/2025 at no cash price and reports beneficial ownership of 300,000 shares directly following the grant. The Form 4 also discloses two stock option holdings: a $1.07 exercise-price option for 125,000 shares granted 12/12/2024 that vests one-third annually, and a fully vested $2.15 exercise-price option for 150,000 shares. The restricted shares vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service.
Citius Oncology director Eugene Myron Holuka acquired 300,000 restricted shares on 09/19/2025 and holds outstanding stock options totaling 275,000 shares. The restricted stock award was granted at no cash price and will vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds a $1.07 strike option for 125,000 shares (granted 12/12/2024, vesting 1/3 annually) and a fully vested $2.15 strike option for 150,000 shares. Following the reported transactions, the reporting person beneficially owns 300,000 shares and options on 275,000 shares directly.